5370 related articles for article (PubMed ID: 3566296)
1. [Antitumor activity of new derivatives of camptothecin].
Nitta K; Yokokura T; Sawada S; Kunimoto T; Tanaka T; Uehara N; Baba H; Takeuchi M; Miyasaka T; Mutai M
Gan To Kagaku Ryoho; 1987 Mar; 14(3 Pt 2):850-7. PubMed ID: 3566296
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothec in, a novel water-soluble derivative of camptothecin, against murine tumors.
Kunimoto T; Nitta K; Tanaka T; Uehara N; Baba H; Takeuchi M; Yokokura T; Sawada S; Miyasaka T; Mutai M
Cancer Res; 1987 Nov; 47(22):5944-7. PubMed ID: 3664496
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity of a new camptothecin derivative, SN-22, against various murine tumors.
Kunimoto T; Nitta K; Tanaka T; Uehara N; Baba H; Takeuchi M; Yokokura T; Sawada S; Miyasaka T; Mutai M
J Pharmacobiodyn; 1987 Mar; 10(3):148-51. PubMed ID: 3625449
[TBL] [Abstract][Full Text] [Related]
4. [Effect of administration schedules on the antitumor activity of CPT-11, a camptothecin derivative].
Furuta T; Yokokura T
Gan To Kagaku Ryoho; 1990 Jan; 17(1):121-30. PubMed ID: 2297233
[TBL] [Abstract][Full Text] [Related]
5. Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice.
Bissery MC; Vrignaud P; Lavelle F; Chabot GG
Anticancer Drugs; 1996 Jun; 7(4):437-60. PubMed ID: 8826613
[TBL] [Abstract][Full Text] [Related]
6. Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse.
Kaneda N; Nagata H; Furuta T; Yokokura T
Cancer Res; 1990 Mar; 50(6):1715-20. PubMed ID: 2306725
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and antitumor activity of 20(S)-camptothecin derivatives: carbamate-linked, water-soluble derivatives of 7-ethyl-10-hydroxycamptothecin.
Sawada S; Okajima S; Aiyama R; Nokata K; Furuta T; Yokokura T; Sugino E; Yamaguchi K; Miyasaka T
Chem Pharm Bull (Tokyo); 1991 Jun; 39(6):1446-50. PubMed ID: 1934165
[TBL] [Abstract][Full Text] [Related]
8. Activity of SC33428, a novel bishydrazone-bridged derivative of 4-demethoxydaunorubicin, against experimental tumors in mice.
Dawson KM
Cancer Res; 1983 Jun; 43(6):2880-3. PubMed ID: 6573953
[TBL] [Abstract][Full Text] [Related]
9. In vivo activity on murine tumors of a novel antitumor compound, N-beta-dimethylaminoethyl 9-carboxy-5-hydroxy-10-methoxybenzo[a]phenazine-6-carboxamide sodium salt (NC-190).
Nakaike S; Yamagishi T; Samata K; Nishida K; Inazuki K; Ichihara T; Migita Y; Otomo S; Aihara H; Tsukagoshi S
Cancer Chemother Pharmacol; 1989; 23(3):135-9. PubMed ID: 2924370
[TBL] [Abstract][Full Text] [Related]
10. In vivo antitumor activity of S 16020-2, a new olivacine derivative.
Guilbaud N; Kraus-Berthier L; Saint-Dizier D; Rouillon MH; Jan M; Burbridge M; Visalli M; Bisagni E; Pierré A; Atassi G
Cancer Chemother Pharmacol; 1996; 38(6):513-21. PubMed ID: 8823492
[TBL] [Abstract][Full Text] [Related]
11. Antitumor spectrum of a new anthracycline, (2"R)-4'-O-tetrahydropyranyladriamycin, and effect on the cellular immune response in mice.
Hisamatsu T; Suzuki K; Sakakibara S; Komuro K; Nagasawa M; Takeuchi T; Umezawa H
Jpn J Cancer Res; 1985 Oct; 76(10):1008-20. PubMed ID: 3935619
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of a new compound, ethyl O-[N-(p-carboxyphenyl)-carbamoyl]-mycophenolate, against various experimental tumors upon oral administration.
Mitsui H; Matsuno T; Ogawa H; Shiio T; Yugari Y; Tamura G
Gan; 1981 Feb; 72(1):66-71. PubMed ID: 7274650
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice.
Kawato Y; Furuta T; Aonuma M; Yasuoka M; Yokokura T; Matsumoto K
Cancer Chemother Pharmacol; 1991; 28(3):192-8. PubMed ID: 1855276
[TBL] [Abstract][Full Text] [Related]
14. Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice.
Kim R; Hirabayashi N; Nishiyama M; Jinushi K; Toge T; Okada K
Int J Cancer; 1992 Mar; 50(5):760-6. PubMed ID: 1312063
[TBL] [Abstract][Full Text] [Related]
15. Recombinant human tumor necrosis factor-alpha: evidence of an indirect mode of antitumor activity.
Manda T; Shimomura K; Mukumoto S; Kobayashi K; Mizota T; Hirai O; Matsumoto S; Oku T; Nishigaki F; Mori J
Cancer Res; 1987 Jul; 47(14):3707-11. PubMed ID: 3594435
[TBL] [Abstract][Full Text] [Related]
16. [Antitumor activity of adriamycin].
Kitaura K; Watanabe Y; Ishihara Y; Takahira H
Jpn J Antibiot; 1972 Apr; 25(2):65-71. PubMed ID: 4341940
[No Abstract] [Full Text] [Related]
17. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11.
Kawato Y; Aonuma M; Hirota Y; Kuga H; Sato K
Cancer Res; 1991 Aug; 51(16):4187-91. PubMed ID: 1651156
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and antitumor activity of 20(S)-camptothecin derivatives. A-ring-substituted 7-ethylcamptothecins and their E-ring-modified water-soluble derivatives.
Yaegashi T; Sawada S; Nagata H; Furuta T; Yokokura T; Miyasaka T
Chem Pharm Bull (Tokyo); 1994 Dec; 42(12):2518-25. PubMed ID: 7697767
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity and hematotoxicity of a new, substituted dihydrobenzoxazine, FK973, in mice.
Shimomura K; Manda T; Mukumoto S; Masuda K; Nakamura T; Mizota T; Matsumoto S; Nishigaki F; Oku T; Mori J
Cancer Res; 1988 Mar; 48(5):1166-72. PubMed ID: 3342397
[TBL] [Abstract][Full Text] [Related]
20. Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo.
Tsuruo T; Matsuzaki T; Matsushita M; Saito H; Yokokura T
Cancer Chemother Pharmacol; 1988; 21(1):71-4. PubMed ID: 3342468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
